Shots:

• Coherus announces the Federal Circuit affirmation decision of the US District Court for the District of Delaware appealing that Coherus’ Udenyca (biosimilar- pegfilgrastim) does not infringe Amgen’s asserted patent 
• On May 10- 2017 under BPCIA act- Amgen filled a patent infringement complaint against Coherus asserting US Patent 8-273-707 (“the ’707 patent”)- further in response Coherus filled lawsuit for dismissing the dispute. In Mar’18 the Delaware Court dismissed the whole case
• Udenyca (pegfilgrastim-cbqv) is a s a PEGylated growth colony-stimulating factor targeted to decrease the incidence of infection- manifested by febrile neutropenia- in patients with non-myeloid malignancies myelosuppressive anti-cancer drugs

Click here to read full press release/ article | Ref: Coherus Biosciences| Image: SmarterAnalyst